Log in

Pfenex Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 10/1/2020)
Today's Range
Now: $12.75
50-Day Range
MA: $12.74
52-Week Range
Now: $12.75
Average Volume503,865 shs
Market Capitalization$437.29 million
P/E RatioN/A
Dividend YieldN/A
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:PFNX



Sales & Book Value

Annual SalesN/A



Market Cap$437.29 million
Next Earnings DateN/A

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pfenex (NASDAQ:PFNX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Pfenex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Pfenex

What stocks does MarketBeat like better than Pfenex?

Wall Street analysts have given Pfenex a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pfenex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Pfenex's key competitors?

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Amarin (AMRN), NVIDIA (NVDA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Viking Therapeutics (VKTX), CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO) and Agile Therapeutics (AGRX).

Who are Pfenex's key executives?

Pfenex's management team includes the following people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 47)
  • Ms. Susan A. Knudson, Sr. VP & CFO (Age 55)
  • Mr. Patrick K. Lucy, Sr. VP & Chief Bus. Officer (Age 51)
  • Dr. Shawn A. Scranton Pharm. D, Sr. VP & COO (Age 55)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 61)

What is Pfenex's stock symbol?

Pfenex trades on the NASDAQ under the ticker symbol "PFNX."

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $12.75.

How big of a company is Pfenex?

Pfenex has a market capitalization of $437.29 million. Pfenex employs 78 workers across the globe.

What is Pfenex's official website?

The official website for Pfenex is www.pfenex.com.

How can I contact Pfenex?

The company can be reached via phone at 858-352-4400.

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.